RE:RE:RE:Interview with Dr. ShahInteresting observation. I also liked his reference to having a treatment for younger patients that exhibit refractory cancers because they have potentially so much more life ahead of them so, as you say, if you can manage it more and provide something measured in many years instead of many months and all with limited side effects, that's an amazing breakthrough. We, and his patients, can only hope to see that proven up in this year.
qwerty22 wrote: I've definitely heard a lot of oncologists talk about cancer almost like a chronic, managed disease where extending life with QoL might be a target outcome rather than cure per se. This also seems to be a path to approval with the fda. So yes very nice very strong responses are desirable but an alternative (or addition) to that is clinical stability and tolerability.
Wino115 wrote: I like that a practitioner refers to this as a "breakthrough" approach. He further equates the need of new therapies to "avoiding side effects". I guess that is a very high desire for doctors to see.
Paraphrasing him -- Living a good life for the period he can control the disease with a treatment.
This drug certainly fits the profile of what he's looking for. Let's hope we see that efficacy.